Anti-inflammatory Respiratory Agents — MCQs
In a patient with COPD, what is the best management option?
A 60-year-old with COPD develops tremor after a medication. Which medication is most likely responsible?
All of the following are indications for use of corticosteroids in SLE except:
Zileuton is:-
Which of the following statements is true regarding omalizumab?
Omalizumab is indicated for which of the following conditions?
Which is the most common side effect of inhaled beclomethasone dipropionate?
Assertion: Acetylcysteine is used to induce sputum for CBNAAT testing in patients suspected of having tuberculosis. Reason: Acetylcysteine acts as a mucolytic agent that helps to liquefy thick respiratory secretions, making it easier to obtain a sputum sample.
Hippus occurs in which poisoning?
A patient comes with a history of asthma and sinusitis. On looking into his medical records, you notice this has been attributed to Samter’s triad. Which drug should be avoided in this patient due to its potential to exacerbate respiratory symptoms?
Anti-inflammatory Respiratory Agents Indian Medical PG Practice Questions and MCQs
Question 1: In a patient with COPD, what is the best management option?
- A. Quit smoking (Correct Answer)
- B. Bronchodilators
- C. Low flow oxygen
- D. Mucolytics
Explanation: ***Quit smoking*** - **Smoking cessation** is the single most effective intervention for slowing the progression of **COPD** and improving lung function [1]. - It reduces exacerbation rates and improves overall mortality, making it the cornerstone of management [1]. *Bronchodilators* - **Bronchodilators** (e.g., beta-agonists, anticholinergics) are crucial for symptomatic relief by opening airways, but they do not alter the disease progression [1]. - While essential for managing symptoms, they are not the "best" in terms of modifying the disease course. *Low flow oxygen* - **Oxygen therapy** is indicated for patients with **severe hypoxemia** (PaO2 < 55 mmHg or SaO2 < 88%) to improve survival and quality of life [2]. - It is a supportive treatment for advanced disease and does not prevent or slow the progression of COPD itself. *Mucolytics* - **Mucolytics** may be used in some patients with COPD and chronic productive cough to reduce sputum viscosity and improve clearance. - Their benefit is primarily symptomatic, and they do not have a significant impact on disease progression or mortality.
Question 2: A 60-year-old with COPD develops tremor after a medication. Which medication is most likely responsible?
- A. Montelukast
- B. Ipratropium
- C. Fluticasone
- D. Salmeterol (Correct Answer)
Explanation: ***Salmeterol*** - Salmeterol is a **long-acting beta-2 agonist (LABA)** commonly used in COPD [1]. Beta-2 agonists can cause **tremor** due to stimulation of skeletal muscle beta-2 receptors [2]. - This side effect is dose-dependent and more common with higher doses or in sensitive individuals. *Montelukast* - Montelukast is a **leukotriene receptor antagonist** used in asthma and allergic rhinitis, not typically a primary agent for COPD, and does not commonly cause tremor. - Its mechanism of action involves blocking leukotriene D4 receptors, which are not directly linked to muscle tremor. *Ipratropium* - Ipratropium is a **short-acting muscarinic antagonist (SAMA)** used in COPD. Its primary side effects are typically anticholinergic, such as dry mouth or blurred vision [3]. - Tremor is not a common or expected side effect of ipratropium as it does not act on beta-adrenergic receptors. *Fluticasone* - Fluticasone is an **inhaled corticosteroid (ICS)** used in COPD, often in combination with LABAs [1]. While systemic corticosteroids can cause tremor, the inhaled form has minimal systemic absorption. - **Inhaled corticosteroids** are primarily associated with local side effects like oral candidiasis or dysphonia.
Question 3: All of the following are indications for use of corticosteroids in SLE except:
- A. Endocarditis (Correct Answer)
- B. Nephritic syndrome
- C. Pericarditis
- D. Neuropsychiatric lupus
Explanation: ***Endocarditis*** - While **Libman-Sacks endocarditis** is a known manifestation of SLE, it typically involves **non-infectious vegetations** and rarely causes significant valvular dysfunction requiring corticosteroid therapy for acute treatment. - Steroids are generally not indicated for the primary treatment of established endocarditis, whether infectious or non-infectious, unless there is a severe active inflammatory component or an autoimmune-driven valvulitis. *Nephritic syndrome* - **Lupus nephritis**, especially the proliferative forms (Class III and IV), often presents with nephritic syndrome and is a **primary indication for aggressive corticosteroid therapy** to suppress inflammation and prevent renal failure [1]. - Corticosteroids are crucial in combination with immunosuppressants to manage renal inflammation, proteinuria, and declining renal function. *Pericarditis* - **Pericarditis** in SLE can be symptomatic and is often managed with **corticosteroids** to reduce inflammation and alleviate chest pain [1]. - Severe or recurrent pericarditis may require higher doses of steroids, and tamponade is a rare but serious complication. *Neuropsychiatric lupus* - Manifestations such as **CNS vasculitis**, **seizures**, psychosis, and severe cognitive dysfunction are considered **major organ involvement** and are treated with **high-dose corticosteroids** to reduce inflammation and prevent permanent neurological damage. - Steroids are often part of the initial treatment regimen for acute and severe neuropsychiatric SLE.
Question 4: Zileuton is:-
- A. Phospholipase inhibitor
- B. Leukotriene receptor antagonist
- C. 5-Lipoxygenase inhibitor (Correct Answer)
- D. Cyclooxygenase inhibitor
Explanation: ***5-Lipoxygenase inhibitor*** - **Zileuton** specifically inhibits **5-lipoxygenase**, an enzyme crucial for the synthesis of **leukotrienes**. - By blocking this enzyme, zileuton reduces the production of **pro-inflammatory leukotrienes**, which are involved in the pathophysiology of **asthma**. *Phospholipase inhibitor* - **Phospholipase A2 inhibitors** like **corticosteroids** act upstream by preventing the release of **arachidonic acid**, a precursor to both prostaglandins and leukotrienes. - Zileuton's action is more specific to the **leukotriene pathway**, occurring after arachidonic acid is already formed. *Cyclooxygenase inhibitor* - **Cyclooxygenase (COX) inhibitors** (like NSAIDs) block the synthesis of **prostaglandins** and **thromboxanes** from arachidonic acid. - Zileuton does not affect the COX pathway but rather targets the **lipoxygenase pathway**. *Leukotriene receptor antagonist* - **Leukotriene receptor antagonists** (e.g., Montelukast, Zafirlukast) block the binding of leukotrienes to their receptors, preventing their downstream effects. - While both target the **leukotriene pathway**, zileuton works by **inhibiting their production**, not their receptor binding.
Question 5: Which of the following statements is true regarding omalizumab?
- A. Anti-IgE
- B. Given subcutaneously
- C. Used as add-on therapy in moderate to severe asthma prophylaxis
- D. All of the options (Correct Answer)
Explanation: ***All of the options*** is correct because each statement is true: **Anti-IgE** - Omalizumab is a **humanized monoclonal antibody** that specifically targets and binds to **free IgE** in the circulation - By binding free IgE, it prevents IgE from attaching to **high-affinity receptors** on mast cells and basophils - This reduces the allergic cascade and prevents release of inflammatory mediators **Given subcutaneously** - Omalizumab is administered via **subcutaneous injection** only - Dosing is typically every **2 to 4 weeks** based on patient's body weight and baseline IgE levels - Not available in oral or intravenous formulations for asthma treatment **Used as add-on therapy in moderate to severe asthma prophylaxis** - FDA approved as **add-on maintenance treatment** for patients aged ≥6 years with **moderate to severe persistent allergic asthma** - Indicated when asthma is **inadequately controlled** with inhaled corticosteroids - Reduces frequency of asthma exacerbations and improves asthma control - Also approved for chronic spontaneous urticaria All three statements accurately describe omalizumab's mechanism, administration route, and clinical indication, making **"All of the options"** the correct answer.
Question 6: Omalizumab is indicated for which of the following conditions?
- A. Multiple myeloma
- B. Psoriasis
- C. Bronchial asthma (Correct Answer)
- D. Rheumatoid arthritis
Explanation: ***Bronchial asthma*** - Omalizumab is an **anti-IgE antibody** that binds to circulating IgE, preventing it from binding to mast cells and basophils, thus reducing allergic reactions. - It is specifically approved for the treatment of **moderate to severe persistent asthma** in patients over 6 years old whose symptoms are inadequately controlled by inhaled corticosteroids. *Multiple myeloma* - Multiple myeloma is a **plasma cell malignancy** affecting bone marrow, for which omalizumab has no approved indication. - Treatment typically involves **chemotherapy**, proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation. *Psoriasis* - Psoriasis is a **chronic inflammatory skin condition** primarily treated with agents targeting inflammatory pathways such as TNF-alpha, IL-17, or IL-23, not IgE. - Common psoriasis medications include **topical corticosteroids**, phototherapy, and systemic biologics like adalimumab or ustekinumab. *Rheumatoid arthritis* - Rheumatoid arthritis is an **autoimmune disease** causing chronic joint inflammation, primarily treated with DMARDs (disease-modifying antirheumatic drugs) and TNF inhibitors. - **IgE does not play a significant role** in the pathogenesis of rheumatoid arthritis, making omalizumab ineffective for this condition.
Question 7: Which is the most common side effect of inhaled beclomethasone dipropionate?
- A. Pneumonia
- B. Oropharyngeal candidiasis (Correct Answer)
- C. Atrophic rhinitis
- D. Pituitary adrenal suppression
Explanation: ***Oropharyngeal candidiasis*** - Inhaled corticosteroids like **beclomethasone dipropionate** can suppress the local immune response in the oral cavity. - This immunosuppression creates an environment conducive to the overgrowth of *Candida albicans*, leading to **thrush**. *Pneumonia* - While inhaled corticosteroids can slightly increase the risk of pneumonia in some populations (e.g., COPD patients), it is **not the most common** side effect. - **Oropharyngeal candidiasis** is much more frequently encountered. *Atrophic rhinitis* - This condition involves inflammation and thinning of the nasal lining, often associated with chronic infections or surgery. - It is **not a typical or common side effect** of inhaled corticosteroids. *Pituitary adrenal suppression* - Systemic absorption of high doses of inhaled corticosteroids can lead to **adrenal suppression**, but this is a **less common and more serious** side effect, usually seen with prolonged high-dose use. - **Oropharyngeal candidiasis** is a local effect and far more prevalent.
Question 8: Assertion: Acetylcysteine is used to induce sputum for CBNAAT testing in patients suspected of having tuberculosis. Reason: Acetylcysteine acts as a mucolytic agent that helps to liquefy thick respiratory secretions, making it easier to obtain a sputum sample.
- A. Assertion is true, Reason is true, and Reason is the correct explanation for Assertion. (Correct Answer)
- B. Assertion is true, Reason is true, but Reason is not the correct explanation for Assertion.
- C. Assertion is false, Reason is false.
- D. Assertion is false, Reason is true.
Explanation: ***Assertion is true, Reason is true, and Reason is the correct explanation for Assertion.*** - The assertion that **acetylcysteine** is used to induce sputum for **CBNAAT testing** in suspected tuberculosis patients is correct. - The reason that acetylcysteine acts as a **mucolytic agent** to **liquefy thick respiratory secretions**, thereby facilitating proper sputum collection, is also correct and directly explains why it is used for this purpose. *Assertion is true, Reason is true, but Reason is not the correct explanation for Assertion.* - While both the assertion and the reason are individually true statements, the reason directly addresses why acetylcysteine is used for sputum induction. - The mucolytic action of acetylcysteine is precisely why it is effective in obtaining adequate sputum samples from patients who may otherwise have difficulty producing them. *Assertion is false, Reason is false.* - The assertion is true because acetylcysteine is a commonly used and effective agent for **sputum induction** in various respiratory conditions, including suspected tuberculosis. - The reason is true because acetylcysteine's primary mechanism of action as a mucolytic, breaking down **disulfide bonds** in mucus, is well-established. *Assertion is false, Reason is true.* - The assertion is indeed true; acetylcysteine is frequently employed in clinical practice to improve the quality of **sputum samples** for diagnostic tests like **CBNAAT**. - The reason is also true, as the **mucolytic properties** of acetylcysteine make it an ideal agent for liquefying thick secretions.
Question 9: Hippus occurs in which poisoning?
- A. Aconite poisoning (Correct Answer)
- B. Opioid poisoning
- C. Neuromuscular blocking agent poisoning
- D. Belladonna poisoning
Explanation: ***Aconite poisoning*** - **Hippus**, characterized by alternating **pupillary constriction and dilation**, is a hallmark of aconite poisoning. - This unusual pupil activity results from the **neurotoxic effects** of aconite on the autonomic nervous system. *Opioid poisoning* - Opioid poisoning typically causes characteristic **pinpoint pupils (miosis)** due to parasympathetic overstimulation. - Hippus is not a feature of opioid toxicity. *Neuromuscular blocking agent poisoning* - Neuromuscular blocking agents primarily affect the **skeletal muscles**, leading to **paralysis** but generally do not directly impact pupil size or reactivity. - Pupils usually remain **mid-dilated and fixed** in severe paralysis, but not hippus. *Belladonna poisoning* - Belladonna (atropine) poisoning causes **mydriasis (dilated pupils)** due to its anticholinergic effect, blocking parasympathetic activity. - The pupils are typically fixed and dilated, not exhibiting hippus.
Question 10: A patient comes with a history of asthma and sinusitis. On looking into his medical records, you notice this has been attributed to Samter’s triad. Which drug should be avoided in this patient due to its potential to exacerbate respiratory symptoms?
- A. Cotrimoxazole
- B. Co-amoxiclav
- C. Chloramphenicol
- D. Aspirin (Correct Answer)
Explanation: ***Aspirin (Correct Answer)*** - Samter's triad, or **aspirin-exacerbated respiratory disease (AERD)**, is characterized by **asthma**, **nasal polyps with chronic rhinosinusitis**, and a severe reaction to **aspirin** and other **NSAIDs**. - **Aspirin** inhibits COX-1, leading to an overproduction of **leukotrienes**, which causes bronchoconstriction and exacerbates respiratory symptoms in susceptible individuals. - This is the drug that **must be avoided** in patients with Samter's triad. *Cotrimoxazole (Incorrect)* - **Cotrimoxazole** (trimethoprim-sulfamethoxazole) is an antibiotic not directly involved in the cyclooxygenase pathway. - While allergic reactions can occur, it is **not specifically contraindicated** in Samter's triad. *Co-amoxiclav (Incorrect)* - **Co-amoxiclav** (amoxicillin/clavulanic acid) is a penicillin-class antibiotic, and its mechanism of action does not involve prostaglandin synthesis. - It does not pose a specific risk for exacerbating respiratory symptoms in patients with **Samter's triad**. *Chloramphenicol (Incorrect)* - **Chloramphenicol** is an antibiotic that inhibits bacterial protein synthesis and is not associated with the pathogenesis of Samter's triad. - It does not impact the **cyclooxygenase or lipoxygenase pathways** that are central to AERD.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free